CM
ALBO

Caption Management’s Albireo Pharma Inc ALBO Stock Holding History

Caption Management’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,300
Closed -$85K – 1959
2022
Q2 		$85K Buy
+4,300
New +$113K ﹤0.01% 1305

Other funds holding ALBO

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Caption Management's ALBO Position: Q3 2022 in Review

Caption Management sold out of Albireo Pharma Inc (ALBO) in Q3 2022, closing a stake of 4,300 shares — an estimated $85K sold.

Caption Management first reported a position in ALBO in Q2 2022 and held it in 1 quarter. The position peaked at $85K in Q2 2022. 108 funds tracked by Wall St. Rank hold ALBO as of Q3 2022.

  • Caption Management reported no remaining Albireo Pharma Inc position as of Q3 2022 after selling out during the quarter.
  • Caption Management sold 4,300 Albireo Pharma Inc shares in Q3 2022, an estimated $85K.
  • Caption Management first reported a position in Albireo Pharma Inc in Q2 2022 and held it in 1 quarter.
  • Caption Management's Albireo Pharma Inc position peaked at $85K in Q2 2022.
  • 108 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q3 2022.

Based on Caption Management's 13F filing for Q3 2022, filed 14 Nov 2022.